Wird geladen...
Cost–Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I
BACKGROUND: Tyrosinemia type I is a rare but severe genetic metabolic disorder. Nitisinone combined with a diet low in tyrosine and phenylalanine became first-line therapy in 1994. OBJECTIVES: To estimate the direct medical costs of health care services related to the treatment of tyrosinemia type I...
Gespeichert in:
| Veröffentlicht in: | Can J Hosp Pharm |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Canadian Society of Hospital Pharmacists
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485508/ https://ncbi.nlm.nih.gov/pubmed/26157182 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|